All In Biotech

Drug Trial Radar · NCT06370273

Thromboprophylaxis in Lower Limb Immobilisation

Thromboprophylaxis in Lower Limb Immobilisation (TiLLI): a Multicentre Study Comprising Two Linked Open Label Phase III Randomised Controlled Trials Evaluating the Effectiveness and Cost Effectiveness of Different Methods of Pharmacological Prophylaxis for Patients With Temporary Lower Limb Immobilisation.

Last checked: Nov 19, 2026Latest source record: Jul 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 10,044 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

10,044

Planned (sponsor's estimate)

Start

Nov 12, 2024

Primary completion

Aug 31, 2028

Study completion Aug 31, 2028

Sponsor

Lead sponsor
Queen Mary University of LondonAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 17, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to find out the clinical and cost effectiveness of Thromboprophylaxis in participants who have been placed in a plaster cast or splint after injury. The main questions it aims to answer are: * whether giving tablets to people at high risks of clots after a leg injury is as good as injections (standard care) * whether giving any medication after a leg injury is better than standard care (advice only) for people at low risk of clots. Participants will be assessed to be high risk (TiLLI High) or low risk (TiLLI Low). People who are at high risk of clots will have either tablets or injections to reduce their risk. People at low risk will receive tablets, injections or no medication. Drug treatments will be provided for the duration of immobilisation or up to 42 days (whichever is earlier), in accordance with current NICE guidelines. The participants will be followed up for 90 days following randomisation.

Conditions

  • Thrombosis
  • Injury Leg

Interventions

  • RivaroxabanDrug

    10mg once daily via oral ingestion

  • ApixabanDrug

    2.5mg twice daily via oral ingestion

  • Enoxaparin Injectable SolutionDrug

    40mg once daily via subcutaneous injection

  • Tinzaparin Injectable SolutionDrug

    4500 IU once daily via subcutaneous injection

  • Dalteparin Injectable SolutionDrug

    5000 IU once daily via subcutaneous injection

  • Fondaparinux Injectable ProductDrug

    2.5 mg once daily via subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite of net clinical benefit comprising clinical VTE event, major bleeding, and cause-specific mortalityTime frame: Within 90 days of randomisation

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Hull Teaching Hospitals NHS Trust

    Hull, United Kingdom · Recruiting

  • Barts Health NHS Trust

    London, United Kingdom · Recruiting

  • Kings College Hospital NHS Foundation Trust

    London, United Kingdom · Recruiting

  • Northern Care Alliance NHS Foundation Trust

    Manchester, United Kingdom · Recruiting

  • Epsom and St Helier University Hospitals NHS Trust

    Carshalton, Surrey, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.